NHS National Framework Agreement for Macitentan & Cladribine Tablets
NHS England
- Value
- £154,080,000
- Published
- 3 Nov 2026
- Deadline
- 17 Nov 2026
- Procedure
- Not stated
- Category
- 33600000 — Pharmaceutical products
- Location
- UKC, United Kingdom
- Notice reference
- 104326-2026
Requirements summary
NHS England is planning a national framework agreement (reference CM/TNS/26/5748) for supply of macitentan and cladribine tablets, split into regional lots across England. Contract periods run from 1 October 2027, mostly to 30 September 2029, with extension options up to 24 months. The notice is a preliminary market engagement notice, and suppliers planning to launch these molecules are invited to register interest by contacting the named NHS contacts.
Key requirements
- Supply of macitentan tablets under CM/TNS/26/5748/01, across three regional lots
- Supply of cladribine tablets under CM/TNS/26/5748/02, across three regional lots
- Framework periods starting 1 October 2027, with lot end dates from 30 September 2028 to 31 January 2029 or 30 September 2029
- Option to extend up to a maximum of 24 months at the Authority's discretion
- Estimated value of GBP 154,080,000 gross (GBP 128,400,000 net)
- Register interest with katie.noonan@nhs.net or marie.graney1@nhs.net and take part in the preliminary market engagement survey by 17 November 2026